Formycon AG
Alexis Rozenknop currently serves as Manager of Clinical Operations at Formycon AG since September 2022, having previously held the role of Associate Manager in the same department. Prior to this position, Alexis worked as Associate Clinical Program Manager at bioeq GmbH from June 2021 to September 2022 and Senior Late Phase Clinical Research Associate at ICON plc from January 2018 to May 2021. Additional experience includes a role as Senior Clinical Research Associate at Mapi Group from June to December 2017, Clinical Research Associate at PPD from March 2012 to May 2017, and Research Assistant roles. Alexis earned a PhD in Biochemistry from Goethe University Frankfurt between 2006 and 2010, complementing a Master’s degree in Biochemistry from Université Paul Sabatier Toulouse III, obtained in 2006. An internship at Sanofi in early 2006 focused on NMR techniques helped complete the Master’s degree.
This person is not in any teams
This person is not in any offices
Formycon AG
1 followers
Who we are Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207 About Biosimilars: Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Global sales of biosimilars are estimated to exceed $15 billion by 2020. By 2030, analysts estimate that this figure could rise to over $60 billion. Contact: Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg Germany phone +49 (0) 89 - 86 46 67 100 fax + 49 (0) 89 - 86 46 67 110 info@formycon.com